Navigation Links
Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
Date:3/31/2008

Kingfisher's Revolutionary Device Designed to Improve Quality of Life for

Patients Suffering From Chronic Pain

ALBUQUERQUE, New Mexico, March 31 /PRNewswire/ -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market KFH Energy in the United States. The patented, high-tech medical device is intended to improve upon quality of life for sufferers of chronic pain associated with post-polio syndrome, fibromyalgia, multiple sclerosis, and chronic fatigue syndrome.

"We are thrilled to introduce KFH Energy to physicians, specialists, and patients throughout the United States," said Dr. Henk Snyman, CEO and co-founder of Kingfisher Healthcare, the parent company of Kingfisher Americas. "Our clinical research on post-polio patients yielded dramatic improvements, and we are eager to address the strong population of chronic pain patients in the U.S. With the proven success of KFH Energy, we anticipate that this technology will be the first in a suite of natural energy devices for a variety of treatments."

KFH Energy utilizes a unique form of micro current electrotherapy called Bio-Electric Stimulation Therapy (BEST), which is designed to enhance the body's physiological processes. Intended for home use, KFH Energy encapsulates this novel technology in a hand-held device. Its sleek and modern design elements, including the patented touch-screen panel, make the device both convenient and easy to use. KFH Energy received CE mark in Europe in September 2007.

"There is a growing demand among individuals with chronic pain for alternative treatments to improve their condition," said Herb Whitaker, CEO of Kingfisher Americas. "We are excited to have this device available in the States and are committed to improving the lives of those who have been sidelined as a result of symptoms." '/>"/>

SOURCE Kingfisher Americas
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
4. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
5. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
6. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
7. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
10. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
11. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...PLEASANTON, Calif., Nov. 9 /PRNewswire-FirstCall/ ...leader in device-based mechanical circulatory supp... hearts, said today that it will be participating ...rence on Tuesday, November 10. ,, The presentat...ive officer, will begin at 8 a.m., Pacific Standar...
(Date:11/9/2009)...SAN DIEGO, Nov. 9 Volcan...velopment, manufacture and sales of products for t...ral artery disease, said today that it will be par...cular Conference on Tuesday, November 10. ,, Th...chief executive officer, will begin at 1 p.m., Pac...
(Date:11/9/2009)...BIRMINGHAM, Ala., Nov. 9 ...that it will host an investor conference call at 1...9, to discuss its 2009 third quarter operating res...tely an hour following the conclusion of the confe.../cgi-bin/prnh/20080812/CLTU111LOGO ) ,, Plea...
Breaking Medicine Technology:Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 2Emission capture study funded for paper industry 10353 1Emission capture study funded for paper industry 10353 2Emission capture study funded for paper industry 10353 3Chimpanzees help each other on request but not voluntarily 10350 1Chimpanzees help each other on request but not voluntarily 10350 2SIMNSA is added to the Satori Global Network 26amp 3B 238482 3B in Mexico to Offer U S Employers Cross Border Health Benefit Options 59446 1SIMNSA is added to the Satori Global Network 26amp 3B 238482 3B in Mexico to Offer U S Employers Cross Border Health Benefit Options 59446 2
...LIS, France, Nov. 20 NicOx S.A. (Eurolist:,COX) t...as dosed the first,patients in a phase 2 proof of ...Pulmonary Disease (COPD) - see TOPIGEN press relea... the first assessment of TPI 1020,s,potential acti...d novel,anti- inflammatory licensed by TOPIGEN fro...
...strated powerful mean blood pressure reductions of... mm Hg diastolic blood pressure (DBP),at five week...ne in a study of patients with se...BP reductions of 27.1/14.6 mm Hg (SBP/DBP), at 8 .../DBP) reductions, respectively for irbesartan and...
Other Medicine Technology:NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 2NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 3NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 4NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 5NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 6NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 7Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7
(Date:11/9/2009)... Networking is everybody,s buzz w... Money. StaffingClub.com enables Recruiters and St...s to connect, share, communicate and close positio...o post their profiles and network with recruiters....09 -- Current Job Market forces everyone to networ...
(Date:11/9/2009)...on of plans finds differences in mood despite simi...thDay News) -- Both a high-fat, low-carbohydrate d...at, high-carb diet appear to help people lose poun...d? Only the low-fat diets will result in long-term...Nov. 9 issue of Archives of Internal Medicine . ,...
(Date:11/9/2009)...ENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Har... , announced today that Novartis, a US$41 billion ...85% stake in HTDS, H1N1 Vaccine partner, Zhejiang ...million. Novartis of Switzerland will begin a five...the company will dramatically increase its investm...
(Date:11/9/2009)... Course, to be Offered in April 2...lkit , Cambridge, MA (Voc...sicians for Human Rights (PHR) first inspected a s...an , he realized he would need a team of experts t...ng the site properly was a key first step in secur...
(Date:11/9/2009)...NTA MONICA, Calif., Nov. 9 Actress...n joined philosophy on Saturday to raise awa...t services throughout California by building heali... Enough kits were created to give one to each of ...one of Los Angeles County,s domestic violence shel...
Breaking Medicine News(10 mins):Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3
...certain cleaning products reduces lung function, i...IDAY, July 25 (HealthDay News) -- A clean, fresh-s...depending on what type of cleaning and air freshen... (VOC) called 1,4 dicholorobenzene (1,4 DCB), can ...
...BROOK, Ill. July 25, 2008 The American Society ...uidelines on the role of endoscopy in the bariatri...y in the United States and the success in surgical...elines discuss endoscopy in the preoperative patie...
... July 25 BeaconEquity.com announces the,availabil... Investors can view all of the daily trading notes..., Today,s Trade Alerts include: DUSA Pharmaceutic...c. (Nasdaq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX...
...nCotter Releases Results of Fourth Annual Physicia...ey, DETROIT, July 25 Sullivan, Cotter and Associ...of physician on-call pay rates and,practices, the ...ctices and rates paid for 33 physician specialty a...
...ays of Marketing Exclusivity Begins -, CORONA, Ca... WPI ), a leading specialty pharmaceutical,compan...ed commercial,shipment of its Omeprazole Delayed-R...f marketing exclusivity for being the,first to fil...
...McKesson Corporation Executive, Robert J. Reilly, ...c.,( http://www.aethon.com ), the leading develope...istics, today announced that Robert J. Reilly has,... Corporation,s Specialty Pharmacy Division, brings...
Other Medicine News:Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2
COULTER AcT diff2 (Recertified)
mini VIDAS - Recertified
ACE Alera
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: